Related references
Note: Only part of the references are listed.
Article
Radiology, Nuclear Medicine & Medical Imaging
Dan Cohen et al.
Summary: The incidence of vaccine-associated hypermetabolic lymphadenopathy (VAHL) is high following the third BNT162b2 dose, with a majority of cases identified within the first 5 days post-vaccination. High-grade VAHL is less likely to be observed on imaging performed 6 days or longer from vaccination, especially in older and obese patients.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Alba Cristina Igual-Rouilleault et al.
Summary: The study aimed to investigate the impact of COVID-19 vaccines on unilateral axillary lymph nodes, comparing their characteristics before and after the first and second doses. Results showed that both doses of the vaccine led to significant increases in all axillary lymph node parameters, especially in patients who were naive to coronavirus infection.
EUROPEAN RADIOLOGY
(2022)
Article
Immunology
Rachael K. Raw et al.
Summary: A survey-based study of healthcare workers in Northeast England was conducted to investigate the influence of previous COVID-19 on vaccine-associated adverse events (AEs). The study found that AEs were worse after the first dose of the vaccine in individuals with prior COVID-19, but the second dose had greater frequency and severity of AEs regardless of COVID-19 history. Women and younger healthcare workers were more likely to report AEs after both doses, while dosing interval did not affect AEs. Ongoing symptomatic COVID-19 was associated with greater frequency and severity of AEs after the second dose. Overall, the AEs were self-limiting and short-lived in nature.
Article
Infectious Diseases
Dong Won Baek et al.
Summary: COVID-19 vaccination has led to a significant decrease in new infections and related deaths, but various adverse events, including hemophagocytic lymphohistiocytosis (HLH), have been reported. This study describes two cases of HLH following vaccination with mRNA-based and adenovirus vector vaccines, emphasizing the importance of early suspicion and management by clinicians to lower mortality rates.
INFECTIOUS DISEASES
(2022)
Article
Immunology
Si'Ana A. Coggins et al.
Summary: The severity of postvaccination symptoms does not correlate with the magnitude of vaccine-induced antibody levels one month after receiving the Pfizer/BioNTech BNT162b2 vaccine. Additional findings include an inverse correlation between symptoms and age/weight, along with more frequent systemic symptoms after the second vaccination and lower antibody titers in older individuals.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Otorhinolaryngology
Kiran Ganga et al.
Summary: COVID-19 vaccination can lead to adverse reactions like lymphadenopathy, but prompt treatment can effectively alleviate symptoms. Lymphadenopathy is reported as a common local reaction to the Moderna vaccine, so enhancing understanding and management of this side effect is important during widespread vaccination efforts.
ENT-EAR NOSE & THROAT JOURNAL
(2021)
Letter
Medicine, General & Internal
Maria Prendecki et al.
Article
Multidisciplinary Sciences
Kenji Maeda et al.
Summary: The study found that the BNT162b2 vaccine can significantly increase neutralizing activity against SARS-CoV-2, but there are differences in different age groups and genders, as well as concerns about the duration of neutralizing capability and effectiveness against variant strains.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Waleed H. Mahallawi et al.
Summary: The study assessed the reactogenicity and immunogenicity of Pfizer and AstraZeneca COVID-19 vaccines among adults in Saudi Arabia. It found that Pfizer vaccine recipients reported fewer vaccine-related complications compared to AstraZeneca vaccine recipients, and the presence of antibodies against the SARS-CoV-2 spike protein may be influenced by factors such as health status and age.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Dimos D. Mitsikostas et al.
Summary: The survey among 1309 healthcare workers revealed that nocebo-prone behavior is associated with SARS-CoV-2 vaccine hesitancy. Female workers and physicians are more likely to report adverse events after vaccination.
Article
Immunology
Alborz Rahmani et al.
Summary: Vaccinations are crucial in combatting the COVID-19 pandemic, with the BNT162b2 mRNA vaccine being widely used in Italy. A study on resident doctors in Genoa revealed common adverse reactions following the first and second doses, with some impacting daily activities for the young working age population.
Article
Immunology
Isabel Iguacel et al.
Summary: The study found that non-overweight individuals were more likely to experience fever, vomiting, diarrhea, and chills after receiving the COVID-19 vaccine. However, when adjusting for age, sex, education, medication, and vaccine administered, most of these associations were not significant.
Article
Geriatrics & Gerontology
Sergio Salmeron Rios et al.
Summary: In a longitudinal cohort study in long-term care facilities in Albacete, Spain, 134 older adults aged >= 65 years received two doses of the BNT162b2 mRNA COVID-19 vaccine, with antibody levels measured 21.9 days after each dose. The vaccine was found to be safe and produced immunogenicity in older adults, regardless of their frailty and disability profiles. Residents with prior COVID-19 infection showed increased antibody levels post-vaccination.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2021)
Article
Infectious Diseases
Cristina Menni et al.
Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.
LANCET INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Joseph E. Ebinger et al.
Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Article
Medicine, General & Internal
Nicola P. Klein et al.
Summary: This study conducted interim analysis of safety surveillance data of mRNA COVID-19 vaccines and found that the incidence of selected serious outcomes within 1-21 days post-vaccination was not significantly higher compared with 22-42 days post-vaccination. Surveillance is ongoing despite wide confidence intervals for many outcomes.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Noam Barda et al.
Summary: The study found that after receiving the BNT162b2 vaccine, most adverse events were not associated with an increased risk, although there was a slight increase in the risk of myocarditis. On the other hand, infection with the Covid-19 virus significantly increased the risk of many serious adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Marco Spadaccini et al.
Summary: The novel Coronavirus has caused nearly 2 million deaths globally, leading to the approval and distribution of COVID-19 vaccines by regulatory agencies. Gastroenterologists are crucial in providing information and guidance on vaccination, especially for vulnerable patients, as vaccination campaigns roll out in the US and Europe.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Article
Immunology
Laura Sanchez-de Prada et al.
Summary: Elderly women exhibit a significantly higher humoral response against classical influenza A (H1N1), pandemic A(H1N1)pdm09, and B/Victoria lineage compared to elderly men. No significant differences were found with the A(H3N2) subtype. Sex dimorphism does not impact young adults.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Wesley H. Self et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Medicine, General & Internal
Theocharis G. Konstantinidis et al.
Summary: This study aimed to evaluate the immunogenic effect of mRNA vaccine against SARS-CoV-2, with results showing a robust immune response in individuals previously infected with the virus compared to non-infected subjects. Interestingly, asymptomatic individuals after vaccination had lower levels of antibodies than those who experienced fever. High levels of anti-Spike COVID-19 antibodies were observed post-vaccination.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Health Care Sciences & Services
Paul Naaber et al.
Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Microbiology
Fabrizio Bonelli et al.
JOURNAL OF CLINICAL MICROBIOLOGY
(2020)
Article
Medicine, General & Internal
David Ellinghaus et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Multidisciplinary Sciences
Ugur Sahin et al.
Article
Public, Environmental & Occupational Health
Sara E. Oliver et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2020)
